Journal
BLOOD
Volume 119, Issue 6, Pages 1479-1489Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2011-07-370841
Keywords
-
Categories
Funding
- Italian Association for Cancer Research [IG8761, IG8727]
- Compagnia di San Paolo [2007.2065, 2010.14038]
Ask authors/readers for more resources
Herein we describe that in classic Hodgkin lymphomas (cHL, n = 25) the lymph node (LN) stroma displayed in situ high levels of transcription and expression of the disulfide-isomerase ERp5 and of the disintegrin-metalloproteinase ADAM10, able to shed the ligands for NKG2D (NKG2D-L) from the cell membrane. These enzymes were detected both in LN mesenchymal stromal cells (MSCs) and in Reed-Sternberg (RS) cells; in addition, MIC-A and ULBP3 were present in culture supernatants of LN MSCs or RS cells. NKG2D-L-negative RS cells could not be killed by CD8(+)alpha beta T or gamma delta T cells; tumor cell killing was partially restored by treating RS cells with valproic acid, which enhanced NKG2D-L surface expression. Upon coculture with LN MSCs, CD8(+)alpha beta T and gamma delta T cells strongly reduced their cytolytic activity against NKG2D-L+ targets; this seems to be the result of TGF-beta, present at the tumor site, produced in vitro by LN MSCs and able to down-regulate the expression of NKG2D on T lymphocytes. In addition, CD8(+)alpha beta T and gamma delta T cells from the lymph nodes of cHL patients, cocultured in vitro with LN MSCs, underwent TGF-beta-mediated down regulation of NKG2D. Thus, in cHL the tumor microenvironment is prone to inhibit the development of an efficient antitumor response. (Blood. 2012; 119(6): 1479-1489)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available